Fig. 2From: Cost-effectiveness analysis of Vaborem in Carbapenem-resistant Enterobacterales (CRE) -Klebsiella pneumoniae infections in ItalyIncremental cost-effectiveness plane. BAT: best available therapy; QALY: quality adjusted life year; PSA: probability sensitivity analysisBack to article page